Excellent - I now have detailed, authoritative content directly from Tintinalli's and Miller's Anesthesia. Here is the comprehensive deep-dive:
Cardiac Arrest & ACLS Drugs - Deep Dive
Sources: Tintinalli's Emergency Medicine, Braunwald's Heart Disease, Miller's Anesthesia (2020 AHA Guidelines)
The Core Principle First
"Good CPR, ventilation, and early defibrillation are the cornerstones of management. Drugs are an adjunct. The effectiveness of standard resuscitative drugs on survival to hospital discharge has not been well demonstrated." - Tintinalli's Emergency Medicine
This is critical: never delay CPR or defibrillation to give a drug.
Drug Administration During Arrest - Key Rules
- Use a proximal peripheral vein (not central - too long, slower delivery)
- Flush with 20 mL normal saline after every drug bolus
- Continue CPR for 30-60 seconds after drug before next defibrillation
- Optimal IV fluid = normal saline (NOT dextrose, Ringer's, or bicarb)
- Endotracheal drug route is no longer recommended - poor absorption in pulmonary edema
- IO access is equivalent to IV for drug doses
1. EPINEPHRINE (Adrenaline)
Class: Endogenous catecholamine
Mechanism:
- Alpha effects (beneficial): Peripheral vasoconstriction → increases coronary perfusion pressure + cerebral blood flow during CPR
- Beta effects (controversial): Increase myocardial work, may reduce subendocardial perfusion
Doses:
| Route | Dose | Indication |
|---|
| IV/IO | 1 mg (10 mL of 1:10,000) | Cardiac arrest (VF, pVT, PEA, Asystole) |
| Repeat | Every 3-5 minutes | No maximum dose |
| IV infusion | 2-10 mcg/min | Cardiogenic shock / symptomatic bradycardia |
Timing matters:
- Non-shockable rhythms (PEA/Asystole): Give epinephrine EARLY - associated with increased ROSC and neurologically intact survival
- Shockable rhythms (VF/pVT): Give after defibrillation attempts; optimal timing less clear
What NOT to do:
- High-dose epinephrine (2-5 mg) is NOT recommended - no benefit in long-term survival
- Do NOT add to alkaline solutions (bicarbonate inactivates it)
- After 20 minutes of arrest, epinephrine may worsen myocardial ischemia and induce VT
Evidence: A 2018 UK RCT showed improved 30-day survival (3.2% vs 2.4%) with epinephrine, BUT survivors had higher rates of severe neurologic disability. Epinephrine helps the heart restart but may worsen brain outcomes.
2. AMIODARONE
Class: Vaughan-Williams Class III - but has properties of ALL 4 classes (Na+, K+, Ca++ channel blockade + beta blockade)
Mechanism: Prolongs action potential duration and refractory period; causes coronary and peripheral vasodilation
Doses:
| Indication | Dose |
|---|
| Pulseless VT / VF (after defib + epinephrine) | 300 mg IV bolus (flush with D5W/saline 20 mL) |
| Second dose if no response | 150 mg IV bolus |
| Hemodynamically stable VT/SVT | 150 mg over 10-15 min, then 1 mg/min x 6 hrs, then 0.5 mg/min x 18 hrs |
Other uses beyond arrest:
- Hemodynamically stable VT / wide-complex tachycardia
- Pharmacologic cardioversion of atrial fibrillation
- Rapid ventricular rate in pre-excitation SVT (WPW)
Adverse effects:
- Hypotension and bradycardia (most common with infusion) - slow the rate, give fluids
- IV solution precipitates in plastic tubing after 2 hours - use glass/polyolefin bottles
Important: A large 2016 multicenter trial (ALPS trial) failed to show survival-to-discharge benefit of amiodarone or lidocaine vs placebo for shock-refractory VF/pVT. Both drugs were better than placebo only in bystander-witnessed arrest for hospital admission.
3. LIDOCAINE
Class: Vaughan-Williams Class IB antiarrhythmic
Mechanism: Sodium channel blocker; suppresses ventricular ectopy; raises VF threshold
Doses:
| Indication | Dose |
|---|
| Pulseless VT / VF (alternative to amiodarone) | 1-1.5 mg/kg IV bolus |
| Repeat bolus (if no response) | 0.5-0.75 mg/kg every 5-10 min |
| Maximum total dose | 3 mg/kg |
| Maintenance infusion | 1-4 mg/min |
When to prefer lidocaine over amiodarone:
- Acute transmural MI as the cause of arrest
- When amiodarone is unavailable
- Either drug is acceptable per 2020 AHA guidelines (no one drug proven superior)
Note: Evidence shows benefit only with IV administration - NOT intraosseous (IO) for improving outcomes.
4. MAGNESIUM SULFATE
Doses:
| Indication | Dose |
|---|
| Torsades de Pointes (polymorphic VT with long QT) | 1-2 g IV over 5-20 min |
| Severe refractory asthma (bronchospasm) | 2 g IV |
| Eclampsia | 4-6 g IV loading dose |
Key point: Routine use of magnesium for VF/pVT is NOT recommended in adults per AHA 2020 guidelines - only for Torsades de Pointes.
5. ATROPINE
Class: Anticholinergic - muscarinic receptor antagonist
Mechanism: Blocks cholinergic (vagal) slowing of SA node and AV conduction → increases heart rate
Doses:
| Indication | Dose |
|---|
| Symptomatic bradycardia | 0.5 mg IV every 3-5 min |
| Max total dose | 3 mg (complete vagal blockade) |
Important caveats:
- NOT used in cardiac arrest (removed from PEA/Asystole algorithm in 2010 AHA guidelines)
- Doses <0.5 mg may cause paradoxical bradycardia (avoid!)
- If atropine fails → use transcutaneous pacing, dopamine, or epinephrine infusion
- May cause myocardial ischemia at high heart rates (use cautiously in known IHD)
6. ADENOSINE
Class: Endogenous purine nucleoside
Mechanism: Activates K+ channels in AV node → transient AV nodal blockade → interrupts re-entry circuits
Doses:
| Indication | Dose | Route |
|---|
| SVT (narrow-complex regular tachycardia) | 6 mg rapid IV push | Proximal vein + 20 mL flush FAST |
| Repeat if no effect (after 1-2 min) | 12 mg IV | Same |
| Third dose if needed | 12 mg IV | Same |
Critical technique: Must be given as a RAPID bolus through a proximal (antecubital or above) vein, immediately followed by a fast 20 mL saline flush. It has a half-life of <10 seconds.
Do NOT use in:
- Pre-excited AF/flutter (WPW with AF) - may cause VF
- Wide-complex tachycardia of uncertain origin unless certain it is SVT with aberrancy
- Significant asthma (can cause bronchospasm)
7. SODIUM BICARBONATE
Doses: 1 mEq/kg IV bolus
When it IS indicated:
- Hyperkalemia with cardiac effects
- TCA (tricyclic antidepressant) overdose - widened QRS
- Salicylate overdose - urinary alkalinization
- Pre-existing metabolic acidosis before arrest
- Prolonged resuscitation (>10-15 min) with arterial blood gas guidance
When it is NOT indicated:
- Routine use in cardiac arrest - NOT recommended (no improvement in ROSC or neurologic outcome)
- pH-guided use only when pH < 7.1 or bicarbonate < 10 mEq/L
8. CALCIUM CHLORIDE / CALCIUM GLUCONATE
| Drug | Dose | Notes |
|---|
| Calcium chloride 10% | 1 g (10 mL) IV | 3x more bioavailable; central/large vein preferred (caustic) |
| Calcium gluconate 10% | 3 g (30 mL) IV | Safer for peripheral vein |
Indications:
- Hyperkalemia with ECG changes
- Hypocalcemia (massive transfusion, dialysis patients)
- Calcium channel blocker overdose
- Beta-blocker overdose (adjunct to glucagon)
- Hypermagnesemia
NOT recommended for routine use during CPR even if ionized Ca++ levels are low.
ACLS Algorithm at a Glance
CARDIAC ARREST
↓
CPR + Rhythm check
↓
┌─────────────────────────────────────────────┐
│ SHOCKABLE (VF / pVT) NON-SHOCKABLE (PEA/Asystole)
│ ↓
│ DEFIBRILLATE Epinephrine 1mg IV ASAP
│ → CPR 2 min (repeat q 3-5 min)
│ → Epinephrine 1mg → Treat reversible causes (H's & T's)
│ (after 1st or 2nd shock)
│ → CPR 2 min
│ → Amiodarone 300mg (after 3rd shock)
│ or Lidocaine 1-1.5 mg/kg
│ → Continue cycles
└─────────────────────────────────────────────┘
The H's and T's - Reversible Causes of Cardiac Arrest
| H's | T's |
|---|
| Hypovolemia | Tension pneumothorax |
| Hypoxia | Tamponade (cardiac) |
| Hydrogen ion (acidosis) | Toxins/overdose |
| Hypo/Hyperkalemia | Thrombosis (pulmonary - PE) |
| Hypothermia | Thrombosis (coronary - MI) |
Treat these simultaneously - no drug will work if the reversible cause is not corrected.
Post-ROSC (Return of Spontaneous Circulation) Care
| Action | Drug/Target |
|---|
| Avoid hypoxia | SpO2 94-98% |
| Avoid hypotension | MAP >65 mmHg - use norepinephrine |
| Targeted Temperature Management | 32-36°C for 24 hours if comatose |
| Treat seizures | Levetiracetam or valproate |
| Treat underlying cause | PCI if STEMI/OHCA |
Sources: Tintinalli's Emergency Medicine (9781260019933), Miller's Anesthesia 10e (9780323935920), Braunwald's Heart Disease (9780323722193), AHA 2020 Guidelines for CPR and ECC.
Would you like to go even deeper into any specific drug, cover pediatric ACLS dosing, or move to another emergency topic like RSI or toxicology?